Alopecia em pacientes anticoagulados

Alopecia em pacientes anticoagulados

Resumo A alopecia é uma complicação comum da terapia anticoagulante que pode ter repercussões psicológicas importantes nos pacientes, especialmente nos do sexo feminino, e interferir na decisão de extensão da anticoagulação. Esta revisão tem como objetivo descrever os mecanismos potencialmente envol...

Full description

Bibliographic Details
Main Authors:	Marcos Arêas Marques, Carmen Lucia Lascasas Porto, Ana Letícia de Matos Milhomens, Juliana de Miranda Vieira, Claudia Carvalho Alcântara Gomes, Ana Thereza Cavalcanti Rocha, Cíntia da Silva Miller
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
Series:	Jornal Vascular Brasileiro
Subjects:	alopecia drug-related side effects and adverse reactions warfarin heparin anticoagulants rivaroxaban
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100406&lng=en&tlng=en

Similar Items

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
by: Jay M. Margolis, et al.
Published: (2016-10-01)

Thromboembolic recurrence frequency analysis in patients with deep vein thrombosis of lower extremities.
by: Sergyi Vasyliuk, et al.
Published: (2020-03-01)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
by: Dong Lin, et al.
Published: (2021-11-01)

Updates in Anticoagulation Therapy Monitoring
by: Hannah L. McRae, et al.
Published: (2021-03-01)

ПРИМЕНЕНИЕ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ И НОВЫЕ ВОЗМОЖНОСТИ
by: Г. И. Сторожаков, et al.
Published: (2013-04-01)

LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME: HOW TO CHOOSE THE PATIENT?
by: A. L. Komarov
Published: (2016-07-01)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
by: So-Ryoung Lee, et al.
Published: (2023-02-01)

Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study
by: Yazed AlRuthia, et al.
Published: (2023-01-01)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
by: Huei‐Kai Huang, et al.
Published: (2020-01-01)

Magnitude of hemorrhagic complications and its associated factors among patients on anticoagulant therapy at University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia
by: Eden Abetu Mehari, et al.
Published: (2023-03-01)

Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
by: Tuukka A. Helin, et al.
Published: (2021-03-01)

Old and New anticoagulants: The beginning of a new era?
by: Fidel Cáceres Loriga, et al.
Published: (2011-01-01)

Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic
by: S. M. Mamatov, et al.
Published: (2021-05-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)

Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study
by: Anneka Mitchell, et al.
Published: (2021-08-01)

The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
by: Brendan Wood, et al.
Published: (2017-08-01)

Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban
by: I S Iavelov
Published: (2013-12-01)

Approaches for the prevention and treatment of venous thromboembolism in a patient with anaplastic astrocytoma: a case report
by: M. G. Pavlova, et al.
Published: (2021-04-01)

Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation
by: Maria Yan, et al.
Published: (2022-05-01)

Anti-Coagulation During Pregnancy in Women with Mechanical Heart Valves: A Prospective Study
by: Amir Jamshid Khamoushi, et al.
Published: (2011-04-01)

Osteoporosis and antithrombotic therapy
by: N. V. Brailova, et al.
Published: (2021-06-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

Knowledge, Attitude and Practice Toward Intracerebral Hemorrhage Prevention Among Patients Taking Oral Anticoagulants
by: Xiao W, et al.
Published: (2024-07-01)

The Effects of 3-Month Rosuvastatin Adjuvant Therapy on Post Thrombotic Syndrome following Deep Vein Thrombosis; a Randomized Clinical Trial
by: Mehdi Pishgahi, et al.
Published: (2023-06-01)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
by: Paolo Zappulla, et al.
Published: (2021-04-01)

Potential for a Virtual Care Model in the Perioperative Management of Anticoagulant Therapy: A 5-Year Retrospective Clinic Review
by: Douketis Douketis, et al.
Published: (2023-07-01)

Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis
by: Huda Moutaz Asmael Al-Azzawi, et al.
Published: (2024-11-01)

Anticoagulation for Radiation-Induced Optic Neuropathy
by: Narayanaswamy Venketasubramanian, et al.
Published: (2020-12-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Changes in prescribing antithrombotic therapy in patients with atrial fibrillation and myocardial infarction in 2016-2019
by: K. G. Pereverzeva, et al.
Published: (2020-08-01)

Safety of ECT in patients receiving an oral anticoagulant
by: Nicolette R. Centanni, PharmD, BCPS, BCGP, BCPP, et al.
Published: (2021-07-01)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
by: Pamela L. Lutsey, et al.
Published: (2019-10-01)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
by: Sonja Hartmann, et al.
Published: (2020-07-01)

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management
by: Martina Mookadam, et al.
Published: (2015-01-01)

Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients
by: Armando Tripodi, et al.
Published: (2023-06-01)